Paper42441024
YAP1 depletion enhances TAZ and its complexation with TEAD4 and AP-1 heterodimer C-JUN/FOSB in gastric cancer progression and metastasis.
Wu J and 24 others. Cancer Heterog Plast, 2026. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. YAP1 depletion enhances TAZ and its complexation with TEAD4 and AP-1 heterodimer C-JUN/FOSB in gastric cancer progression and metastasis. Papers, record 42441024. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42441024
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- YAP1 depletion enhances TAZ and its complexation with TEAD4 and AP-1 heterodimer C-JUN/FOSB in gastric cancer progression and metastasis.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 CA230323 | NCI NIH HHS | United States | R01CA230323 | PubMed | NIH RePORTER |
| R01 CA269685 | NCI NIH HHS | United States | R01CA269685 | PubMed | NIH RePORTER |
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Update of | 41292957 | YAP1 Depletion Enhances TAZ and its Complexation with TEAD4 and AP-1 Heterodimer C-JUN/FOSB to Promote Gastric Cancer Progression and Metastases. | https://conductscience.org/library/papers/41292957 |
Source PubMed
References37
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 37277530 | An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance. | Nat Cancer | 2023 | https://conductscience.org/library/papers/37277530 | PubMed |
| 2 | 32175692 | Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma. | Mol Oncol | 2020 | https://conductscience.org/library/papers/32175692 | PubMed |
| 3 | 23536563 | Loss of TGF-β adaptor β2SP activates notch signaling and SOX9 expression in esophageal adenocarcinoma. | Cancer Res | 2013 | https://conductscience.org/library/papers/23536563 | PubMed |
| 4 | 28035666 | Roles and regulations of Hippo signaling during preimplantation mouse development. | Dev Growth Differ | 2017 | https://conductscience.org/library/papers/28035666 | PubMed |
| 5 | 32345613 | YAP1 mediates gastric adenocarcinoma peritoneal metastases that are attenuated by YAP1 inhibition. | Gut | 2021 | https://conductscience.org/library/papers/32345613 | PubMed |
| 6 | 35550144 | NOTCH-YAP1/TEAD-DNMT1 Axis Drives Hepatocyte Reprogramming Into Intrahepatic Cholangiocarcinoma. | Gastroenterology | 2022 | https://conductscience.org/library/papers/35550144 | PubMed |
| 7 | 33850002 | Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of NF2-deficient Mesothelioma. | Mol Cancer Ther | 2021 | https://conductscience.org/library/papers/33850002 | PubMed |
| 8 | 36002248 | Epithelial SOX9 drives progression and metastases of gastric adenocarcinoma by promoting immunosuppressive tumour microenvironment. | Gut | 2023 | https://conductscience.org/library/papers/36002248 | PubMed |
| 9 | 39630608 | YAP1 induces bladder cancer progression and promotes immune evasion through IL-6/STAT3 pathway and CXCL deregulation. | J Clin Invest | 2024 | https://conductscience.org/library/papers/39630608 | PubMed |
| 10 | 24715453 | The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease. | Development | 2014 | https://conductscience.org/library/papers/24715453 | PubMed |
| 11 | 37419119 | Evolution of immune and stromal cell states and ecotypes during gastric adenocarcinoma progression. | Cancer Cell | 2023 | https://conductscience.org/library/papers/37419119 | PubMed |
| 12 | 39817679 | Cancer statistics, 2025. | CA Cancer J Clin | 2025 | https://conductscience.org/library/papers/39817679 | PubMed |
| 13 | 29696628 | A time for YAP1: Tumorigenesis, immunosuppression and targeted therapy. | Int J Cancer | 2018 | https://conductscience.org/library/papers/29696628 | PubMed |
| 14 | 29665979 | Crosstalk between YAP/TAZ and Notch Signaling. | Trends Cell Biol | 2018 | https://conductscience.org/library/papers/29665979 | PubMed |
| 15 | 34162421 | Patient-derived cell lines and orthotopic mouse model of peritoneal carcinomatosis recapitulate molecular and phenotypic features of human gastric adenocarcinoma. | J Exp Clin Cancer Res | 2021 | https://conductscience.org/library/papers/34162421 | PubMed |
| 16 | 29167315 | A Novel YAP1 Inhibitor Targets CSC-Enriched Radiation-Resistant Cells and Exerts Strong Antitumor Activity in Esophageal Adenocarcinoma. | Mol Cancer Ther | 2018 | https://conductscience.org/library/papers/29167315 | PubMed |
| 17 | 38572751 | Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. | CA Cancer J Clin | 2024 | https://conductscience.org/library/papers/38572751 | PubMed |
| 18 | 37849539 | Novel Indazole Compounds as TEAD Inhibitors for Treating Cancer. | ACS Med Chem Lett | 2023 | https://conductscience.org/library/papers/37849539 | PubMed |
| 19 | 36347846 | The Hippo signalling pathway and its implications in human health and diseases. | Signal Transduct Target Ther | 2022 | https://conductscience.org/library/papers/36347846 | PubMed |
| 20 | 38443968 | Inhibition of MER proto-oncogene tyrosine kinase by an antisense oligonucleotide enhances treatment efficacy of immunoradiotherapy. | J Exp Clin Cancer Res | 2024 | https://conductscience.org/library/papers/38443968 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42131796 | Rewiring transcriptional plasticity: the case for dual YAP1 and TAZ targeting in gastric cancer peritoneal metastases. | Cancer Heterog Plast | 2026 | https://conductscience.org/library/papers/42131796 |
Source PubMed
Genes26
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42441024
GET https://conductscience.org/api/papers/v1/42441024/authors?page=2